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D
PRAbstract
A mix of biocompatible macromolecules (poly(vinyl alcohol) (PVA) and poly(vinyl pyrrolidone) (PVP)) has been shown previously to
enhance the physical stability of non-aqueous pharmaceutical suspensions. The aim of this work was to assess the feasibility of employing such a
combination to facilitate the formulation of deoxyribonuclease I (DNase I) in a metered dose inhaler (MDI) using hydrofluoroalkane (HFA)
propellants. DNase I was combined with the selected excipients and formed into an inhalable microparticle by spray-drying. When spray-dried
alone DNase I lost almost 40% of its original biological activity, but stabilising DNase I with trehalose and PVA (DTPVA) retained 85% biological
activity and trehalose, PVA and PVP (DTPVAPVP) retained 100%. Suspending the DTPVAPVP microparticles within a HFA pMDI for 24 weeks
led to no further reduction in the biological activity of DNase I and the formulation delivered almost 60% of the dose expelled to the second stage
of a twin-stage impinger. The solubility of PVP in HFA propellants suggests that the enhanced physical stability observed with PVA and PVP may
partially be as a result of steric stabilisation. However, the large zeta potential associated with the suspensions suggested that charge stabilisation
may also influence the pMDI physical stability.
© 2006 Elsevier B.V. All rights reserved.38
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RR1. IntroductionDeoxyribonuclease I (DNase I) is a hydrophilic glycosylatedprotein with a molecular mass of approximately 33 kDa [1]. It is
an endonuclease, which degrades DNA through the hydrolysis
of the P–O3′ bond, yielding 5′-oligonucleotides [2]. The
biological activity of DNase I is catalysed by divalent cations
and it has previously been shown to exhibit optimal activity in
the presence of Ca2+, Mg2+ or Ca2+ and Mn2+ [3]. DNase I
readily digests both single and double stranded DNA, but the
enzyme reaction occurs at a rate of at least four orders of
magnitude slower with a single stranded substrate [2].
DNase I has been employed clinically as a mucolytic since
the 1960's because the breakdown of DNA within purulent
sputum leads to a dramatic reduction in the viscosity of airway
secretions. However, after a reported case of bronchospasm
caused by an immunogenic response to the bovine form of the
protein, the clinical applications of DNase I fell into disuse [4].56
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doi:10.1016/j.jconrel.2006.06.003Subsequent development of recombinant DNA technology has
allowed the production of a humanised form of DNase I
(rhDNase I). rhDNase I lacks the immunogenicity of bovine
DNase I and as a result rhDNase I is now licensed in numerous
countries worldwide for the symptomatic relief of cystic fibrosis
[5–7].
Whilst rhDNase I is highly effective in breaking down
viscous mucus in the airways, its clinical use is limited by the
fact that it is delivered using a nebuliser (Pulmozyme®).
Although atomisation of a drug solution into droplets using a
nebuliser avoids the often-problematic fabrication of a particu-
late-based drug delivery system, these devices are not favoured
by patients due to their lack of portability and low delivery
efficiency.
Pressurised metered dose inhalers (pMDIs) incorporate
compounds within an air tight, light protective, low moisture
environment and therefore provide excellent protection for
labile therapeutics such as proteins [8]. However, hydrophilic
proteins such as rhDNase I are typically poorly soluble within
non-polar HFA propellants. Thus, to enable the delivery of such
agents via pMDIs, the therapeutic protein must be formulated asCOREL-04227; No of Pages 8
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a particulate that can be suspended within the pMDI propellant.
In order to minimise chemical and physical instability within a
suspension pMDI a desirable compatibility between the
propellant and the particulate (containing the protein) must be
achieved within the formulation reservoir. In addition, upon
dose actuation, the pMDI must reproducibly release a homo-
geneous aliquot of the particulate suspension which upon
evaporation of the propellant must produce particles with
suitable aerodynamic characteristics to deposit within the
airways. Furthermore, it is essential that the protein's biological
activity is maintained during the formulation manufacturing
process and over the product shelf-life.
Despite the complexity of formulating proteins within
pMDIs, preliminary studies by Quinn and co-workers [9]
have found (using Fourier transform Raman spectroscopy) that
lysozyme undergoes no change in the presence of the pMDI
propellant HFA 134a. However, whilst the potential of pMDIs
to delivery proteins effectively has been reported previously,
few details have been published on the suspension stability,
biological activity, structural integrity and aerodynamic char-
acteristics of such formulations during long-term storage. In
addition, the mechanism by which these hydrophilic labile
macromolecules remain physically and chemically stable in
hydrophobic solvents is currently unknown.
As such, the objective of this study was to investigate the
feasibility of formulating DNase I within an HFA-based pMDI
for pulmonary delivery. In an attempt to try and achieve this
aim, a number of stabilising excipients, previously shown to
improve the physical stability of HFA suspensions, were
combined with the protein using spray-drying [10,11]. The
excipients were selected with a view to improving both the
chemical and physical stability of the protein during manu-
facture and storage within the pMDI.
2. Materials and methods
2.1. Spray-drying the DNase I formulations
Approximately 500 mg of DNase I (deoxyribonuclease I
isolated from the bovine pancreas, high purity, Rnase free,
14,200 U/mg, defined by Sigma Aldrich as Genotech® units,
supplied by Sigma Aldrich, UK) was added to 100 ml sodium
chloride solution (10 mM) containing a number of different
combinations of excipients (Table 1) which included PVA 80%
hydrolysed (Mw of 8000–10,000, Sigma Aldrich, UK),
trehalose dihydrate (Sigma Aldrich, UK) and PVP K15U
144
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Table 1
Compositions of the spray-dried microparticulate formulations containing
DNase I
Formulation Composition
DNase I SD DNase I 500 mg
DT DNase I 500 mg–trehalose 500 mg
DTPVA DNase I 500 mg–trehalose 500 mg–PVA 80%
hydrolysed 500 mg
DTPVAPVP DNase I 500 mg–trehalose 500 mg–PVA 80%
hydrolysed 500 mg–PVP K15 500 mgTE
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(10,000 Mw Sigma Aldrich, UK). The excipients were dissolved
in solution by simple stirring using a magnetic hotplate (Stuart
Scientific, UK). When PVAwas included within the solution it
required heating for 30 min at 90 °C to facilitate dissolution of
the polymer after which the solution was allowed to cool to
room temperature prior to addition of the protein. DNase I was
carefully added to the solution containing the excipients using
gentle rotation by hand to facilitate dissolution.
DNase I microparticles were produced from the solutions
using a 191 mini spray-dryer (Buchi, Germany). The protein/
excipient(s) solutions were pumped through a spray atomisation
nozzle that combined the liquid with a 700 ml h−1 airflow
delivered to the drying chamber. The aspiration rate was set as
70%, the material feed rate was 3 ml min−1 and the inlet
temperature was set to 95 °C. The outlet temperature was found
to be in the range of 65–70 °C. The final spray-dried product
was collected on wax paper and stored in a desiccator
containing phosphorous pentoxide (Sigma Aldrich, UK) prior
to use. The yield was calculated as the solid mass collected at
the end of the spray-drying process as a percentage of the initial
solid weight of the excipients in the feed stock solution.
2.2. Microparticle characterisation
Approximately 2 mg of spray-dried powder was dispersed in
1 ml of 0.1% w/v lecithin (Sigma Aldrich, UK)–cyclohexane
(BDH, Germany) solution and sonicated in a water bath (Model
F5100b; Decon Laboratories, UK) for 30 s to disperse any
possible agglomerates before a small sample of the suspension
was added to a stirred sample cell again containing approxi-
mately 0.1% w/v lecithin–cyclohexane solution as the disper-
sion media. The particle size of the sample was measured using
a laser diffraction analyser (Malvern Instruments, UK) fitted
with a 63 mm focal length lens at an obscuration of 0.165–0.25.
Particle size distributions were expressed in terms of D(v,0.9), D
(v,0.5), and D(v,0.1) which were the respective diameters at 90,
50 and 10% cumulative volumes.
2.3. pMDI manufacture
The pMDIs were manufactured by adding the equivalent of
15.0 mg of the raw drug (calculated using the % of the DNase I
content of the microparticles) directly into a poly(ethylene
terephthalate) canister (donated by Astrazeneca, UK). A 25 μl
canister valve (donated by Astrazeneca, UK) was crimped in
place using a manual pMDI filler (Pamasol, Switzerland) and
20.0 g of HFA 134a (Dupont, Germany) or 17.5 g HFA 227
(Solvay, Germany) was pressure-filled into the can via the valve.
The formulation was then sonicated in an ultrasonication bath
(Decon Laboratories, UK) for 15 s to ensure particle separation
and stored, valve up, at room temperature. Several batches of
each formulation were manufactured and utilised in the study.
2.4. DNase I biological stability in HFA
The DNase I pMDIs were stored at room temperature ‘valve
up’ for 24 weeks. Immediately upon manufacture and after 2, 4,
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12 and 24 weeks, the secondary structure, deposition character-
istics and biological activity of DNase I were determined using
the methods detailed below.
2.5. DNase I quantification
The Pierce Protein Assay® was performed as per the
manufacturer's instructions. BSA was used as the protein
standard and a set of BSA solutions between 2 and 20 μg ml−1
was prepared by diluting the 2.0 mg ml−1 standard with
deionised water (conductivity 0.5–1.0 μS). The working
reagent was prepared by mixing 25 parts of Micro BCA reagent
A (sodium carbonate, sodium bicarbonate, sodium tatrate in
0.2 M sodium hydroxide), 24 parts of reagent B (aqueous
solution of BCA detection reagent) and 1 part of reagent C (4%
cupric sulfate pentahydrate). An aliquot of 150 μl of each
standard or test sample was transferred into separate wells of a
96-well microplate in duplicate and 150 μl of the working
reagent was subsequently added to each well and the plate
mixed on a plate shaker for 30 s. The plate was covered with its
lid (to prevent significant evaporation) and incubated at 50°C
for 90 min, after which it was cooled to room temperature and
the UVabsorbance in each well determined using a plate reader
at a wavelength of 562 nm. The amount of enzyme in each test
sample was determined as a nominal concentration against the
BSA protein standard calibration curve.
2.6. Assay of DNase I biological activity
The biological activity of DNase I was monitored by
assessing the ability of the enzyme to digest the substrate, DNA.
The substrate was constituted in a 0.1 M, pH 5.0 acetate buffer,
containing 5 mM Mg2+. The buffer was prepared by dissolving
1.165 g of anhydrous sodium acetate (BDH, Germany), 0.355 g
of acetic acid (Sigma Aldrich, UK) and 0.203 g of MgCl2·6H2O
(Sigma Aldrich, UK) in 150 ml of deionised water (conductivity
0.5–1.0 μS). Approximately, 2 mg of fibrous DNA isolated
from a calf thymus (Sigma Aldrich, UK) was dissolved in 52 ml
of the acetate buffer by gently shaking overnight. The
absorbance of this substrate solution at 260 nm was determined
to be between 0.630 and 0.690. Prior to assessing the test
samples, a DNase I standard, 2000 Kunitsz units mg−1 (Sigma
Aldrich, UK), was used as a calibrant for the activity assay. This
standard was constituted by dissolving the supplied powdered
enzyme in 1.0 ml of 0.15 M NaCl solution. The solution was
diluted further with 0.15 M NaCl to obtain five separate
standard solutions within the concentration range of 20–
80 units ml−1. All dilutions were performed using 0.15 M
NaCl solution. The wavelength of a lambda 5 UV spectro-
photometer (Perkin-Elmer, UK) was adjusted to a 260 nm and
2.5 ml of substrate was placed into a cuvette (10 mm light path)
and incubated in a thermostatic cell (25 °C) for 3–4 min to allow
temperature equilibration. Then, 0.5 ml of diluted standard, or
sample, was added and the solutions were immediately mixed
by inversion. The increase in the UV absorbance per min
(ΔA260) was recorded as a function of time for 10–12 min. An
activity calibration curve was constructed by plotting theTE
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maximum ΔA260 vs. Kunitz units mg−1 of the five DNase I
activity standards. The DNase I samples were diluted to attain a
ΔA260 within the calibration range and activity measured as
before. The Pierce Protein Assay® was then used to quantify the
protein, to obtain the activity per mg. This was compared to the
activity of the lyophilised raw DNase I to produce the % relative
activity.
2.7. Impaction analysis
The twin-stage impinger (TSI) was employed to determine
the deposition characteristics of the microparticles after release
from the pMDIs. The TSI apparatus was set up and run using a
flow rate of 60 l min−1 in accordance with the method set out in
the British Pharmacopeia [12]. The pMDIs were primed prior to
use by discharging approximately 10 shots into a fume
cupboard. A total of 20 actuations were sprayed into the
apparatus from each inhaler. The pump was allowed to run for
5 s after each discharge and then switched off for 5 s whilst the
inhaler was shaken by hand. After the completion of each run
the impinger was dismantled and the drug assayed according to
the amounts deposited on the device, stage 1 and stage 2. The
device was washed with 50 ml of deionised water (conductivity
0.5–1.0 μS) and both stage 1 and 2 with 100 ml of deionised
water. The Pierce Protein Assay® (described above) was used to
quantify the DNase I within the washing solutions.
The quantities of DNase I delivered by the pMDI
formulations on each stage of the impinger were determined
as a percentage of the total quantity of the protein recovered
from the device and the impinger. For example, in order to
calculate the stage 2% deposition, Eq. (1) was used:
%stage2 ¼ Qa
Qa þ Qb þ Qc
 
100 ð1Þ
where %stage2 is the percentage of the DNase I on stage 2 of the
impinger, Qa is quantity of the DNase I on stage 2 of the im-
pinger, Qb is the quantity of the DNase I on stage 1 of the
impinger, Qc is the quantity of the DNase I on the device. The
fine particle fraction (FPF) was defined as the % of the DNase I
on stage 2 of the impinger, i.e. the % of particles <6.4 μm.2.8. Zeta potential
A Zeta Sizer Nano NS® (Malvern instruments, UK) was
used to measure the zeta potential. Samples were prepared by
suspending approximately 2 mg of the powder in a surrogate
solvent dichloromethane (DCM) (selected on the basis of a
previous study [13], BDH, Germany) and sonicating the
mixture for 1 min in a 5300b ultrasonication bath (Decon
Laboratories, UK). The zeta potential of the samples was
measured immediately after suspension within the solvent
using a DTS1070 non-aqueous dip cell (Malvern Instruments
Ltd, UK). A total of 20 runs were performed for each sample
using a cell voltage of 20 V. Three different suspensions were
made up and measured for each of the batches of micro-
particles. The conversion of the measured electrophoretic
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ARTICLE IN PRESSmobility (Ue) into zeta potential (z) was carried out using
Henry's equation (Eq. (2)):
Ue ¼ 2ezf ðKaÞ3g ð2Þ
where ε is the dielectric constant, η is the sample viscosity and
f(Ka) is Henry's function. The parameter K, termed the Debye
length is a measure of the thickness of the electrical double
layer. In aqueous solutions this f(Ka) is approximated to be
1.5, known as the Smoluchowski approximation. However, for
small particles in non-aqueous solvents this approximation
becomes 1.0 (referred to as the Huckel approximation) and this
was used in this study.C
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3. Results
3.1. Microparticle characterisation
The particle size measurements of the spray-dried micro-
particles immediately after preparation indicated that all of the
batches were of a suitable size for drug delivery to the airways,
i.e. the median diameters of all the particles were less than 5 μm
(Table 2). The smallest median particle diameter (Dv, 0.5–1.94
±0.14 μm) was produced by spray-drying the protein with PVA,
PVP and trehalose (DTPVAPVP). Compared to spray-drying
DNase I alone, the incorporation of additional stabilising
excipients increased the yield of the manufacturing method
from 15.40% to ca. 40%. All of the DNase I microparticles
exhibited <5% variance in their protein content implying that
they incorporated a very uniform distribution of the protein. DT
PVA contained the highest DNase I content at 50.17±2.95%
which was significantly more (p<0.05, ANOVA) than the
DTPVAPVP microparticles which had the lowest DNase I
content at 43.84% (Table 2).
3.2. DNase I biological stability in HFA
The biological activity of the spray-dried DNase I micro-
particles was compared to the original material immediately
after manufacture and at four time points after suspension
within a HFA propellant, with a view to separating the effects of
the manufacturing process and storage within the HFA
propellants on the DNase I. The DNase I SD lost almost 40%
of its original activity as a consequence of the spray-drying
process however, suspension within HFA did little to degrade
the protein any further (Fig. 1A). The addition of trehalose to340
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Table 2
Particle size, manufacture yield and DNase I content of the spray-dried
microparticles (mean±SD, yield n=1, rest n=3)
Sample Yield
(%)
Dv, 0.1
(μm)
Dv, 0.5
(%)
Dv, 0.9
(μm)
DNase I
(%)
DNase I SD 15.40 1.00±0.02 2.25±0.15 4.52±0.52 –
DT 40.00 1.34±0.03 2.87±0.17 5.65±0.59 48.36±4.76
DTPVA 34.75 1.24±0.01 3.06±0.12 6.57±0.43 50.17±2.95
DTPVAPVP 39.60 1.09±0.12 1.94±0.14 3.35±0.30 43.84±2.95TE
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DNase I within the spray-dried microparticulates (Fig. 1B)
significantly improved (p<0.05 Mann–Whitney test) the
biological activity of the protein during the 26 week stability
study, but the DT microparticles did still loose approximately
20% of their original enzymatic activity after spray-drying.
Storage of DNase I stabilised with trehalose in HFA 134
propellant over 24 weeks did not induce any further reduction of
biological activity (Fig. 1B). Using PVA and trehalose to
stabilise DNase I (DTPVA Fig. 1C) significantly improved
(p<0.05, ANOVA) the retention of the enzymes biological
function during spray-drying (85.34±2.18%) compared to
DNase I stabilised with trehalose alone (78.33±3.20%).
When the DTPVA microparticles were suspended within both
HFA 134a and HFA 227 some of the activity that appeared to
have been lost as a result of spray-drying was recovered (Fig.
1C and E). DTPVA recovered less of its original activity when
suspended in HFA 134a compared to when suspended in HFA
227 and retained a significantly higher biological activity over
the 24 week period (p<0.05Mann–Whitney test). The DNase I
microparticles containing trehalose, PVA and PVP
(DTPVAPVP) were the only spray-dried formulation to retain
100% of its activity after the manufacturing process (Fig. 1D).
The activity of the enzyme within the DTPVAPVP micro-
particles immediately after manufacture was significantly
higher (p<0.05, ANOVA) than any of the other DNase I
microparticles produced using spray-drying.
3.3. Impaction analysis
The pMDI containing DNase I SD microparticles emitted the
highest FPF compared to any of the other DNase I HFA
formulations, depositing ca. 60% of its metered dose onto stage
2 of the TSI (Table 3). The pMDI containing the DT
microparticles produced a significantly lower (p<0.05,
ANOVA) FPF compared to the protein formulated alone
through out the 24 week stability study. In a similar manner
to DNase I SD there was no significant difference (p>0.05,
ANOVA) in FPF emitted from the DT pMDI throughout the
time frame of the stability study (Table 3). Using trehalose and
PVA to suspend DNase I (DTPVA) within HFA 134a resulted in
a similar FPF to the DT formulation for the first 2 sample time
points in the stability study (ca. 42%). However, the FPF for the
DTPVA HFA 134a formulation dropped to ca. 30% at the
24 week time point which was significantly lower (p>0.05,
ANOVA) than that any of the other DNase I pMDIs. In addition
to the low FPF, the deposition variability of the DTPVA 134a
formulation increased dramatically during 24 weeks of storage
at room temperature (Table 3). The suspension of DTPVA
within HFA 227 produced an FPF of approximately 45% which
was not significantly higher (p>0.05, ANOVA) compared to
that from the DT or DTPVA 134a formulations. In addition,
neither the FPF (p<0.05, ANOVA) nor the deposition
variability changed dramatically over the 24 week time frame
(Table 3). The combination of PVP, PVA and trehalose
(DTPVAPVP) proved to be the best set of excipients with
which to physically stabilise the DNase I within a HFA pMDI
(Table 3).
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Fig. 1. Biological activity of DNase I microparticles alone (A) or formulated with trehalose, DT (B), trehalose and PVA, DTPVA 134a (C) trehalose and PVA and PVP
DTPVAPVP (D), when stored at room temperature for 24 weeks within an HFA 134a metered dose inhalers. In addition (E) displays the biological activity of DNase I
formulated with trehalose and PVA, DTPVA 227, when stored at room temperature for 24 weeks within a HFA 227 metered dose inhaler (n=3, mean±standard
deviation).
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3.4. Mechanism of excipient mediated stabilisation
Although the zeta potential distribution was found to be
consistently broad when it was measured for the DNase I
microparticles suspended in DCM, the measurements were
highly reproducible (Fig. 2). The phase plot was clearly defined,
with mobility in both directions (inferred by the positive and
negative gradient in Fig. 2) when using a fast reversing micro-
electrophoresis method. Spray-dried DNase I alone suspended
in DCM produced a zeta potential of 66±4 mV, DT 67±3 mV,U
Table 3
The fine particle fraction of the pMDI formulations obtained from the five
DNase I HFA pMDIs after 2, 4, 12 and 24 weeks of storage at room temperature
(mean±SD, n=3; the recovery was >75% in all cases)
Formulation FPF week
2 (%)
FPF week
4 (%)
FPF week
12 (%)
FPF week
24 (%)
DNase I SD 59.6±4.5 61.8±3.5 69.2±6.5 52.4±9.5
DT 44.6±6.7 42.2±5.1 37.5±5.2 42.8±0.4
DTPVA 134a 42.0±0.6 42.0±0.6 23.0±5.6 31.6±12.4
DTPVA 227 45.1±7.2 50.6±5.2 47.2±5.2 50.1±0.7
DTPVAPVP 51.0±0.9 48.3±5.6 56.9±1.7 57.8±1.7DTPVA 61±18 mV, DTPVAPVP 70±9 mV. There was no
significant difference between the measured zeta potentials of
the three batches of the excipient stabilised DNase I
microparticles compared to DNase I SD (p>0.05, ANOVA).Fig. 2. Zeta potential distribution and phase plot for the suspension of DNase I
SD microparticles within dichloromethane, n=3.
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4. Discussion
Although DNase I was initially combined with different
ratios of stabilising excipients this ratio was not maintained
during spray-drying. As is often the case when generating
microparticles from solution feed stocks the excess excipients
form very small <1 μm size particles and lost waste whilst the
excipients associated with the protein form the microparticles
>1 μm that can be collected in the cyclone of the spray-drying
apparatus. As a result the final microparticles in each case
contained approximately 50% of DNase I.
Microparticulate fabrication methods involving spray-drying
can render peptides and proteins susceptible to inactivation.
Trehalose is commonly used as a protectant during protein
particle engineering techniques and was used in this study to
protect DNase I against the stresses encountered during spray-
drying [14,15]. It is thought that sugars stabilise proteins during
rapid dehydration through either vitrification or water substitu-
tion mechanisms. Water substitution, a thermodynamic process,
involves the formation of hydrogen bonds between the sugar
and protein, which is believed to be responsible for the
inhibition of the unfolding of the proteins. Vitrification, a
kinetic process, depends upon the immobilisation of protein
molecules during glass formation [14,16]. Although the exact
mechanism of trehalose stabilisation was not identified in this
work the sugar was able to conserve 90% of the proteins
biological activity compared to 60% when the DNase I was
spray-dried alone.
IN addition to heat induced dehydration, the process of
spray-drying exposes macromolecules to high shear and rapidly
forming air–water interfaces. Whilst trehalose is known to
protect DNase I against the removal of water, there is little
evidence that it is effective in protecting therapeutic agents
against the surface effects caused by atomisation. In the current
study, even when trehalose was employed as a stabiliser the
DNase I lost >ca. 10% of its biological activity. The exposure of
the protein molecules to the high interfacial tension that occurs
during spray-drying may account for this loss in activity.
Surface active, high molecular weight compounds, such as PVA
and bovine serum albumin (BSA), have previously been shown
to act as sacrificial molecules in order to protect labile peptides
and proteins agents against denaturation caused by high
interfacial tension [17]. However, in this study, the addition of
PVA to trehalose had little effect on the loss of biological
activity of the protein during particulate manufacture. Adsorp-
tion of a compound at the air–liquid interface of liquid droplets,
such as those formed during the process of spray-drying, is
dependent upon both diffusion and convection. Whilst the PVA
used in this study is smaller than DNase I, and therefore should
diffuse to the droplet surface more rapidly, this is based on the
assumption that the two molecules do not interact. In addition,
both compounds are macromolecules which adopt only a
discrete number of conformations and it is difficult to predict if
certain functionalities within the molecules will adsorb to the
interface preferentially. As the addition of PVA to the
microparticles had little effect on the 10% loss in the DNase I
activity when formulated with trehalose, it appears that whilstTE
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PVA might adsorb to the surface of the droplets as they dry, this
does not occur exclusively, otherwise it would be expected to
protect the protein from denaturation. Therefore, DNase I is still
potentially being denatured by adsorption at the air–liquid
interface when trehalose and PVA are used as excipients during
the spray-drying process.
In contrast to DNase I formulated with trehalose and PVA,
the addition of both PVA and PVP did enhance the protection of
the protein during spray-drying. PVA has been shown to interact
with PVP and should such an interaction between the polymers
occur within the aqueous environment of the droplet, any
preferential adsorption of the polymers to the air–liquid
interface simply driven by diffusion may be inhibited as the
movement of the PVA/PVP composite would be slowed [18].
However, in the event of PVA and PVP interacting during the
spray-drying of DNase I, the surface migration of the composite
may be a consequence of the greater hydrophobicity of the
associated polymers which would increase the driving force
acting on the polymers to orientate at the air interface. Whilst
the protein is also known to possess significant hydrophobic
regions these will be shielded within a structure exhibiting a
high order of conformation. In contrast, the two polymers, even
if associated in some way, are likely to exhibit a less constrained
conformation, thus preventing the protein from distributing at
the surface of the spray-dried droplets by reducing the
interfacial tension.
The DNase I microparticles were suspended in a volatile
HFA solvent after spray-drying. In-situ analysis of the
structural stability of heat sensitive proteins within solvents
exhibiting a high vapour pressure such as hydrofluoroalkanes at
present using commercially available equipment is impossible.
Preliminary work by Quinn et al. [9,19] and other workers have
demonstrated that model proteins such as lysosyme did not
undergo structural modifications upon suspension within HFA
propellants [20]. However, since this initial discovery, there has
been little subsequent work to formulate therapeutic proteins
within pMDIs. DNase I is a much more labile protein compared
to lysosyme; it is physically unstable upon storage within
aqueous solution at room temperature and it is susceptible to
glycation in the dry-state. Regardless of its greater suscept-
ibility to denaturation, the high stage 2 deposition of the DNase
I when formulated without stabilising excipients in the TSI
implied that the microparticle suspension was physically stable
in the propellant. Furthermore, the unchanging biological
integrity of the protein upon storage within the propellant
suggested that the protein was structurally stable [21]. It is
however difficult to draw definitive conclusions on the
compatibility of DNase I alone with the hydrofluroalkane
solvents as the protein microparticles formed without stabilis-
ing excipients had been significantly denatured during spray-
drying. If the denaturation of the protein was as a result of a
change in secondary structure then hydrophobic moieties
within the protein's structure may have been externalised
changing the microparticle surface and this could enhance the
protein–HFA compatibility. Clearly further work is required to
investigate the influence of protein denaturation upon HFA
compatibility in more detail.
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In low dielectric solvents the barrier to charging is up to forty
times larger compared to a polar suspension vehicle and
therefore, the charge effects within non-polar systems should be
insignificant. According to Henry's equation if the Debye
length is assumed constant (Huckel approximation) then in a
low dielectric constant media a low electrophoretic mobility
would indeed result in a low zeta potential. However, the zeta
potential measurements of the spray-dried microparticles were
all in excess of −60 mV. DNase I microparticles exhibited a
similar charge when suspended within DCM irrespective of the
included stabilising excipients. This however, again may not be
a true reflection of what is occurring in the non-polar
suspensions as the DNase I alone was shown to be denatured
and therefore may present a more hydrophobic surface.
The ionisation of the folded protein in the buffer solution
prior to spray-drying should have been negative according to
theoretical calculations based on its amino acid sequence.
However, the DNase I when spray-dried alone produced a +ve
zeta potential. The surface charge will be dependent upon the
conformation the protein has taken when it dried into the
microparticle droplet. The charging of particles in non-polar
solvents such as DCM is not necessarily due to the location of
amino- and carboxy-terminus of the peptide as according to the
dielectric constant of the non-polar solvent it would contain very
few ionisable species. When the DNase I was spray-dried with
stabilising excipients the protein should have taken a different
conformation (as it is biologically active), but the zeta potential
is very similar irrespective of the type of excipient included, this
suggests therefore that it may not be the amino acids on the
surface of the microparticle that are inducing the surface charge,
but other ionic processes such as charging induced by absorption
of impurities or proton exchange as described by Farr et al.
(1994) [21].
Whilst care has to be taken when extrapolating the effects
observed in a ‘surrogate’ non-polar system (in this case
DCM) to those that can occur in HFA propellants it is evident
that charge is present when the DNase I particles are
suspended in non-polar systems and this effect may contribute
to the excellent physical suspension stability of the suspen-
sion. Even in inert non-polar systems counterions are present,
possibly in part due to trace impurities. Yu et al. [22] showed
the effect of water on zeta potential using a series of
homologous solvents. The simple addition of 0.5% water to a
non-polar system provided a one order of magnitude rise in
zeta potential. These workers also linked a decrease in the
magnitude of zeta potential within suspension systems to a
decrease in dielectric constant. In contrast, Kosmulski [23]
concluded that the role of water in non-polar systems is
“overrated” whilst the role of trace impurities such as amines
is often overlooked. Regardless of the source and nature of
the counterions, the results obtained in the present study
appeared to support the observations that charge can have an
important role in the physical stabilisation of pharmaceutically
relevant non-polar suspensions. However, further work is
required to investigate the origin of this charge and to
determine whether it can be controlled to promote physical
stability in non-polar systems.TE
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Ridder et al. [24] showed that HFA 227 (C3HF7)
demonstrates stronger interactions with common surfactants
such as Brij and Tween compared to HFA 134 (C2H2F4) due to a
greater capacity to form hydrogen bonds. Despite both PVA and
PVP being water soluble polymers both molecules contain
hydrophobic moieties. Solvation effects as a result of the
presence of PVP, which has been shown to be sparingly soluble
in the HFA, are thought to promote limited chain extension and
steric stabilisation [10,25,26]. Steric effects usually result from
the adsorption of surfactants or polymers on the surface of the
particles and subsequent chain extension however, the very
limited solubility of PVA in HFA would not be expected to
result in this polymer extending into the HFA. More
fundamental studies using model systems are required to
characterise the mechanism of the protein microparticle
stabilisation and to isolate the factors that might enhance the
physical stability of the microparticles. However, the results
from this study suggest that both the charge generated on the
particle surface, perhaps as a result of proton exchange with
HFA 227 as demonstrated previously with small molecular
weight surfactants and the steric stabilisation via the use of
appropriate polymer excipients could be of relevance to the case
of DNase I [21].
5. Conclusion
The pMDI system developed in this work could provide a
suitable alternative to the nebuliser solution currently used to
administer DNase I. Incorporating this protein into an HFA
system not only stabilised the macromolecule at room
temperature, but in addition, produced a formulation that is
both portable and easy to use. Protection gained from the non-
polar vehicle probably due to the low availability of water, air
and light, which are the most common degradations for
pharmaceutical compounds, resulted in two of the formulations
being both physically and biologically stable over a 6 month
stability study.
This study builds on previous work to show that the
combination of PVA and PVP can be used to aid the physical
stability of suspension based pMDIs [10,27,28]. Although the
technical challenges of measuring the zeta potential directly
within HFA systems have not yet been solved, this work
provides some evidence that both steric hindrance (due to the
incorporation of PVP) and electrostatic stabilisation could be
functioning to aid the stabilisation of microparticles within non-
polar systems. The high zeta potential of the particles in DCM
which has an identical dielectric constant to HFA 134a indicates
that whilst the electrostatic forces did not seem to be the sole
influence on the physical stability of DNase I, DT, PVA and
PVP microparticles, charge may play an important role in pMDI
stabilisation.
Acknowledgements
The authors wish to thank MedPharm and King's College
London for the financial support of this project. In addition,
special thanks goes to Malvern Instruments UK and in
C586
587
588
589
590
591
592
593
594
595
596
597
598
599
600
601
602
603
604
605
606
607
608
609
610
611
612
613
614
615
616
617
618
619
620
621
622
623
624
625
626
627
628
629
630
631
632
633
634
635
636
637
638
639
640
641
642
643
644
645
646
647
648
649
650
651
652
653
654
655
656
657
658
659
660
661
662
663
664
665
666
8 S.A. Jones et al. / Journal of Controlled Release xx (2006) xxx–xxx
ARTICLE IN PRESSRE
particular Michael Kaszuba for the use of the Nano Series® Zeta
Sizer.
References
[1] I. Gonda, Inhalation therapy with recombinant human deoxyribonuclease I,
Adv. Drug Deliv. Rev. 19 (1) (1996) 37–46.
[2] M. Laskowski, in: P.D. Boyer (Ed.), The Enzymes, Academic Press, New
York, 1971, pp. 289–311.
[3] C. Oefner, D. Suck, Crystallographic refinement and structure of Dnase-I
at 2A resolution, J. Mol. Biol. 192 (3) (1986) 605–632.
[4] P. Raskin, Bronchospasm after inhalation of pancreatic dornase, Am. Rev.
Respir. Dis. 98 (1968) 597–598.
[5] M. Berge, E. Wiel, H.A.W.M. Tiddens, P.J.F.M. Merkus, W.C.J. Hop, J.C.
de Jongste, DNase in stable cystic fibrosis infants: a pilot study, J. Cyst.
Fibros. 2 (4) (2003) 183–188.
[6] P.L. Shah, S.F. Scott, R.A. Knight, C. Marriott, C. Ranasinha, M.E.
Hodson, In vivo effects of recombinant human DNase I on sputum in
patients with cystic fibrosis, Thorax 51 (2) (1996) 119–125.
[7] C. Ranasinha, B. Assoufi, S. Shak, D. Christiansen, H. Fuchs, D. Empey,
D. Geddes, M. Hodson, Efficacy and safety of short-term administration of
aerosolized recombinant human Dnase-I in adults with stable stage cystic-
fibrosis, Lancet 342 (8865) (1993) 199–202.
[8] C. Vervaet, P.R. Byron, Drug–surfactant–propellant interactions in HFA
formulations, Int. J. Pharm. 186 (1) (1999) 13–30.
[9] E.A. Quinn, R.T. Forbes, A.C. Williams, M.J. Oliver, L. McKenzie, T.S.
Purewal, Protein conformational stability in the hydrofluoroalkane
propellants tetrafluoroethane and heptafluoropropane analysed by Fourier
transform Raman spectroscopy, Int. J. Pharm. 186 (1) (1999) 31–41.
[10] S.A. Jones, G.P. Martin, M.B. Brown, High-pressure aerosol suspensions
—a novel laser diffraction particle sizing system for hydrofluroalkane
metered dose inhalers, Int. J. Pharm. 302 (2005) 154–165.
[11] S.A. Jones, G.P. Martin, M.B. Brown, Metered Dose Inhaler Preparations
of Therapeutic Drugs, PCT/GB2004/005172, 2004.
[12] British Pharmacopoeia, Stationary Office, London, UK, 2004.
[13] S.A. Jones, G.P. Martin, M.B. Brown. Manipulation of beclomethasone–
hydrofluoroalkane interactions using biocompatible macromolecules,
J. Pharm. Sci. (in press).
[14] T. Arakawa, S.J. Prestrelski, W.C. Kenney, F.C. Carpenter, Factors
affecting short-term and long-term stabilities of proteins, Adv. Drug Deliv.
Rev. 10 (1) (1993) 1–28.UN
CO
RTE
D
PR
OO
F
[15] Y.H. Liao, M.B. Brown, T. Nazir, A. Quader, G.P. Martin, Effects of
sucrose and trehalose on the preservation of the native structure of spray-
dried lysozyme, Pharm. Res. 19 (12) (2002) 1847–1853.
[16] J.F. Carpenter, K. Izutsu, T.W. Randolph, in: L. Rey, J.C. May (Eds.),
Freeze-Drying/Lyophilization of Pharmaceutical and Biological Products,
New York, 1999, pp. 123–160.
[17] W. Wang, Lyophilization and development of solid protein pharmaceu-
ticals, Int. J. Pharm. 203 (1–2) (2000) 1–60.
[18] S.A. Jones, G.P. Martin, M.B. Brown, Biocompatible polymer blends: the
effects of physical processing on the molecular interaction of polyvinyl
alcohol and polyvinylpyrrolidone, J. Appl. Polym. Sci. 98 (2005)
2290–2299.
[19] E.A. Quinn, The stability of proteins in hydrofluoroalkane propellants,
PhD thesis, University of Bradford, 2000.
[20] Y.H. Liao, M.B. Brown, S.A. Jones, T. Nazir, G.P. Martin, The effects of
polyvinyl alcohol on the in vitro stability and delivery of spray-dried
protein particles from surfactant-free HFA 134a-based pressurised metered
dose inhalers, Int. J. Pharm. 304 (1–2) (2005) 29–39.
[21] S.J. Farr, L. McKenzie, J.G. Clarke, Drug–surfactant interactions in apolar
systems: relevance to the optimised formulations of suspension MDIs,
Respir. Drug Deliv. IV (1994) 221–230.
[22] J.C. Yu, Z.T. Jiang, H.Y. Liu, J. Yu, Influence of solvation interactions on
the zeta potential of titania powders, J. Colloid Interface Sci. 262 (1)
(2003) 97–100.
[23] M. Kosmulski, Zeta potentials in nonaqueous media: how to measure and
control them, Colloids Surf., A Physicochem. Eng. Asp. 159 (2–3) (1999)
277–281.
[24] K.B. Ridder, C.J. vies-Cutting, I.W. Kellaway, Surfactant solubility and
aggregate orientation in hydrofluoroalkanes, Int. J. Pharm. 295 (1–2)
(2005) 57–65.
[25] B.A.D. Costello, I.T. Kim, P.F. Luckham, T.F. Tadros, Experimental
investigations of the interaction forces in concentrated dispersions,
Colloids Surf., A Physicochem. Eng. Asp. 77 (1) (1993) 55–63.
[26] D.H. Napper, Flocculation studies of non-aqueous sterically stabilized
dispersions of polymer, Trans. Faraday Soc. 64 (1968) 1701.
[27] S.A. Jones, G.P. Martin, M.B. Brown, Development of a rapid pre-
formulation screen for HFA suspension metered dose inhalers, Drug Deliv.
Lung IX (2004) 529–532.
[28] S.A. Jones, Y.H. Liao, G.P. Martin, M.B. Brown, Metered dose inhaler
preparations, WO 2004/043442, 2003.
